- Home
- BLRX
BLRX
BioLineRx Ltd.
as of 12-26-2025 10:54am EST
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
| Founded: | 2003 | Country: | Israel |
| Employees: | 28 | City: | N/A |
| Market Cap: | 12.6M | IPO Year: | 2011 |
| Target Price: | $19.00 | AVG Volume (30 days): | 23.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.30 - $14.70 | Next Earning Date: | 11-24-2025 |
| Revenue: | $12,735,000 | Revenue Growth: | -42.09% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered BLRX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare BLRX vs Leading Stocks
See how BLRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BLRX BioLineRx Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.